All In MedTech

FDA Clearance Tracker · P040013-S023

GEM215 Growth Factor Enhanced Matrix

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 17, 2020 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P040013-S023
Device name
GEM215 Growth Factor Enhanced Matrix
Applicant location
Franklin, TN
Received
Mar 24, 2020
Decided
Jun 17, 2020
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P040013

Device type

Device class
Class III
Regulation
21 CFR 872.3930

Every decision under product code NPZ

FDA's approval statement

As written in FDA's record.

Approval for change of the supplier from STERIS (formerly Synergy Health) in Swindon, United Kingdom (STERIS Swindon), to the STERIS AST facility located at 9 Apollo Drive, Whippany, New Jersey, United States (STERIS Whippany), for sterilization of the ?-TCP cup component of the GEM21S device.

Source documents

Other decisions for Lynch Biologics, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.